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Abstract
Lesions of ERBB2, PTEN, and PIK3CA activate the phosphati-
dylinositol 3-kinase (PI3K) pathway during cancer development
by increasing levels of phosphatidylinositol-3,4,5-triphosphate
(PIP3). 3-Phosphoinositide-dependent kinase 1 (PDK1) is the
first node of the PI3K signal output and is required for
activation of AKT. PIP3 recruits PDK1 and AKT to the cell
membrane through interactions with their pleckstrin homology
domains, allowing PDK1 to activate AKT by phosphorylating it
at residue threonine-308. We show that total PDK1 protein and
mRNA were overexpressed in a majority of human breast
cancers and that 21% of tumors had five or more copies of the
gene encoding PDK1, PDPK1. We found that increased PDPK1
copy number was associated with upstream pathway lesions
(ERBB2 amplification, PTEN loss, or PIK3CA mutation), as well
as patient survival. Examination of an independent set of breast
cancers and tumor cell lines derived from multiple forms of
human cancers also found increased PDK1 protein levels
associated with such upstream pathway lesions. In human
mammary cells, PDK1 enhanced the ability of upstream lesions
to signal to AKT, stimulate cell growth and migration, and
rendered cells more resistant to PDK1 and PI3K inhibition.
After orthotopic transplantation, PDK1 overexpression was not
oncogenic but dramatically enhanced the ability of ERBB2 to
form tumors. Our studies argue that PDK1 overexpression and
increased PDPK1 copy number are common occurrences in
cancer that potentiate the oncogenic effect of upstream lesions
on the PI3K pathway. Therefore, we conclude that alteration of
PDK1 is a critical component of oncogenic PI3K signaling in
breast cancer. [Cancer Res 2009;69(15):6299–306]
Introduction
ERBB2/HER2/Neu (human epidermal growth factor receptor 2),
PTEN (phosphatase and tensin homologue deleted on chromo-
some ten), and PIK3CA (encodes the p110a subunit of phospha-
tidylinositol 3-kinase [PI3K]) frequently contribute to breast
carcinoma (BC) progression through their ability to regulate the
intracellular level of phosphatidylinositol-3,4,5-triphosphate (PIP3;
refs. 1–5). 3-Phosphoinositide-dependent kinase 1 (PDK1), a serine
threonine kinase known as the master AGC [cyclic AMP
dependent, cyclic guanosine 3¶,5¶-monophosphate dependent, and
protein kinase C] kinase, activates the catalytic domain of over
20 other kinases by phosphorylating their T-loops (6). PDK1 is
the first node of the PI3K signal output and is required for
activation of AKT (protein kinase B, PKB), S6K (p70 ribosomal S6
kinase), and RSK (p90 ribosomal S6 kinase) in vivo (7). PDK1 kinase
activity is constitutive with regulation typically occurring through
phosphorylation of the substrate hydrophobic pocket by other
kinases (8–10). In the case of AKT, the interaction of the pleckstrin
homology (PH) domain of AKT with membrane bound PIP3 confers
a conformational change in AKT, which allows PDK1 to
phosphorylate AKT at residue threonine-308 (T-308; refs. 11–13).
Although the roles of many individual PDK1 substrates remain
to be defined, the oncogenic activity of aberrant PI3K pathway
signaling through PDK1 to AKT has been extensively validated.
Murine Akt was originally isolated as an oncogene (14), and human
AKT isoforms are altered in tumors (genomic amplification of
AKT2 in pancreatic and ovarian cancer and activating PH domain
mutations of AKT1 in BC and AKT3 in melanoma; refs. 15–17). AKT
has many substrates that define its diverse oncogenic outputs from
cell growth and survival to angiogenesis, migration, and invasion
(18). Targeting AKT1 and AKT2 in tumor cell lines with a small
molecule inhibitor has a profound antitumor effect when PIK3CA is
mutated or ERBB2 is amplified (19).
PDK1 is oncogenic in the Comma-1D immortal murine
mammary cell model, but its role in human cancers is yet to be
fully elucidated (20, 21). Its oncogenic effect in mice seems to
function via the PI3K pathway, because Pten+/ tumor formation
was severely attenuated when bred with Pdk1 hypomorphic mice
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with 10% of normal Pdk1 enzyme (22). Two previous reports
suggested increased phosphorylated PDK1 protein levels in the
majority of human BCs, both by immunohistochemistry (IHC)
analysis with a phosphorylated-specific antibody (21, 23), yet the
significance of this overexpression is unclear.
We have found that total PDK1 is overexpressed in a large
proportion of human BCs and have found that many harbor an
increased copy number (ICN) of the gene encoding PDK1, PDPK1 .
Hypothesizing that PDK1 could amplify the PI3K signal output, we
discovered that increased PDK1 was associated with PI3K pathway
lesions (ERBB2/PTEN/PI3K) in a highly annotated set of human
sporadic BCs (24). This notion was further validated in human
mammary cell lines wherein increased PDK1 in multiple settings of
upstream activation [due to ERBB2 or PIK3CA mutation or PTEN
RNA interference (RNAi)] enhanced AKT activation and rendered
some cell lines less sensitive to both PDK1 and PI3K inhibition.
PDK1 overexpression was insufficient to promote tumor growth of
orthotopically transplanted human mammary epithelial MCF10A
cells, but dramatically enhanced the tumor growth and invasion of
cells overexpressing ERBB2. We thus propose a model in which
coincident lesions with PDK1 overexpression on the same signaling
pathway enhance PI3K signaling to promote cellular transforma-
tion and postulate that PDK1 expression levels may alter the
efficacy of PI3K pathway–targeted cancer therapy.
Materials and Methods
Patient samples. BC samples were obtained from the Columbia
University Tumor Bank (Columbia cohort) in accordance with institutional
review board approval. Tissue microarrays were created from 172 unique
BCs and 78 corresponding normal breast tissues with three cores embedded
per sample.
Plasmids. PDPK1 sequence was PCR amplified from p-FAST-BAC-
myc-PDK1 ( from Dr. Dario Alessi, University of Dundee) with primers
5¶-CGCGTCGACGCCAGGACCACCAGCCAGCT and 5¶-GCGGCCGCCTGCA-
CAGCGGCGTCCGGG and cloned into XhoI-NotI sites of pOZ-FH-N (25).
pBABE-NeuT was obtained from Dr. Nancy Hynes at the Friedrich Miescher
Institute.
IHC. PDK1 staining was on paraffin sections [PKB kinase (E-3) Santa
Cruz, 1:300] microwave antigen retrieval in citrate, detected by EnVision+
(Dako). The PDK1 IHC score was determined by fraction of cells showing
cytoplasmic staining (0–1) multiplied by staining intensity rated from 0 to 6
to give a score from 0 to 6. Both BC and nonneoplastic breast epithelium
was separately evaluated. PTEN IHC was performed as described (24) with
the following modifications: PTEN antibody (Cell Signaling, 138G6) 1:200,
microwave retrieval in Target Retrieval Solution pH 9 (Dako), and signal
detection using EnVision+ (Dako).
Fluorescence in situ hybridization and chromogenic in situ
hybridization. A BAC clone (RP11-67B18) spanning PDPK1 gene was
obtained from BACPAC Resources.13 A green-labeled CEP 16 probe (Abbott
Molecular) was used for chromosome 16. A case was considered to have
ICN for PDPK1 if at least 25% of cells contained greater or equal to five
copies. ERBB2 chromogenic in situ hybridization (CISH) was performed as
described (26).
Tissue culture. Phoenix-ampho cells for retrovirus production were
provided by Dr. Gary Nolan, Stanford University. After transfection, the
virus was stabilized with fetal bovine serum (FBS; 6:1 v/v viral supernatant/
FBS) and passed through a 0.45-Am filter. Morphogenesis assay performed
as described for MCF10A (27). Cells were fed on days 3, 5, and 7. Pictures
were taken, and cells were harvested on day 16.
Immunoblotting. Whole-cell lysates were used in immunoblots. Anti-
bodies were from Cell Signaling, except for PDK1 (Upstate 06-906), PDK1
(BD Biosciences 611070) or PKB kinase (E-3; Santa Cruz sc-17765),
h-tubulin (clone Tu27, Covance), PTEN (6H2.1, Cascade Bioscience), and
c-Neu (Ab-3, Calbiochem).
Migration assay. Cells (8  104) in assay media (DMEM/F12, 0.5% horse
serum, 0.5 Ag/mL hydrocortisone, 100 ng/mL cholera toxin, 10 Ag/mL
insulin, penicillin/streptomycin) were placed in the upper chambers of
8-Am 24-well Transwell cell culture plates (Costar), and the assay was
performed as described (27).
AKT RNAi migration. MCF10A cells with and without stable over-
expression of PDK1 were infected with short hairpin RNA (shRNA) lentiviral
vectors targeting AKT1 and/or AKT2 or empty pLKO.1 control vector (AKT1
hairpin sequences: sense, 5¶-CCGGgagtttgagtacctgaagctgCTCGAGcagctt-
caggtactcaaactcTTTTTG-3¶ and antisense, 5¶-AATTCAAAAAgagtttgagtacct-
gaagctgCTCGAGcagcttcaggtactcaaactc-3¶; AKT2 hairpin sequences: sense,
5¶-CCGGgcgtggtgaatacatcaagacCTCGAGgtcttgatgtattcaccacgcTTTTTG-3¶;
antisense, 5¶-AATTCAAAAAgcgtggtgaatacatcaagacCTCGAGgtcttgatgtatt-
caccacgc-3¶). At 48 h after infection, Transwell migration assays were
performed. Relative migration of MCF10A cells is expressed as the ratio of
the number of cells that migrated to the lower surface of the membrane
over that of control (cells infected with pLKO.1 vector).
Mouse studies. Animal procedures were performed in compliance with
Columbia University Institutional Animal Care and Use Committee within
Institute of Comparative Medicine. Seven-week-old SCID/NCr (BALB/c
background) mice (NCI catalogue number 01S11) were injected s.c. with
1.5  106 into inferior mammary fat pad. Mice were monitored daily for
general health and tumor growth. Mice were sacrificed 6 mo after injection
or when tumors reached a surface area of 1 cm2, as measured by caliper
(surface area of tumor = length  width).
Protein lysate array. As described previously (28, 29), interrogating total
PDK1 (Cell Signaling 3062) and PDK1 phosphorylated on residue serine 241
(PDK1pS241; Cell Signaling 3061).
PDK1 shRNA. The shRNA lentiviral particles targeting PDK1 (SHVRS-
NM_002613) and nontarget shRNA control transduction particles
(SHC002V) were purchased from Sigma-Aldrich. The shRNA transductions






Nontarget control (CTRL): ccggcaacaagatgaagagcaccaactcgagttggtgctctt-
catcttgttgttttt.
Proliferation and IC50 assays. Cells (3–5  103) were plated on 48-well
dishes and left at room temperature for 1 h before 37jC incubation. At 12 to
16 h later, cells were washed and media was changed. At the day of harvest,
cells were stained with 0.05% crystal violet in 10% formalin, washed, and
incubated with 10% acetic acid before a 590-nm absorbance was measured
(BIO-TEK). Curve fit (using XLfit4) with model 205 with parameters A and B
locked at 0 and 100, respectively.
Statistics. We compared clinical and pathologic tumor characteristics
and their association with increased PDPK1 copy number (z5 copies and
V4 copies) using m2 test (and Fisher’s exact test when sample counts
were small). To test the distribution differences displayed via box plot, the
Mann-Whitney test was used.
Results
PDK1 is overexpressed with increased genetic copy number
in human BC. Because PDK1 is overexpressed in many human BC
cell lines (20), we evaluated total PDK1 expression levels by IHC in
a set of human BC samples (Fig. 1A). Although there was variation
among cases in the level of PDK1 staining in nonneoplastic breast
epithelium, we found that membranous and cytoplasmic PDK1
staining was significantly higher in BC cells than in adjacent13 http://bacpac.chori.org
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normal duct cells (P < 0.0001; Fig. 1B). Overall, increased PDK1
protein levels (defined as an IHC score of z5) were observed in 72%
(50 of 69) of the cases. The specificity of the antibody was tested
both by immunoblot and IHC of paraffin-embedded cells with
RNAi knockdown of PDK1 (Supplementary Fig. S1A and B).
To test the hypothesis that the increase in PDK1 expression was
due to increased gene copy number, we performed interphase
fluorescence in situ hybridization (FISH; Fig. 1C). We found that
21% (27 of 129) of BCs had at least five copies of PDPK1 , which we
define as ICN. On average the ICN cases had seven copies of
PDPK1 , over a 3-fold increase above normal tissue (which always
had two copies), and a 2-fold increase over the average number of
chromosome 16 centromere copies. Although PDPK1 ICN cases
had increased PDK1 expression above that of normal ducts, they
had only a slightly higher IHC score distribution than low copy
number tumor cases (V4 copies), indicating that ICN is only one
mechanism of PDK1 overexpression (Fig. 1B). PDPK1 ICN was
confirmed by Southern blot (Supplementary Fig. S1D), in which 10
of 49 cases (20%) showed an increased signal, consistent with the
frequency of ICN by FISH. Of the 24 cases in which we also had
FISH data, three of four ICN cases gave an increased Southern
signal, whereas only 2 of 20 cases without ICN did (P = 0.02). We
also sequenced the PDPK1 gene in 124 human BCs and found one
somatic mutation (P340A). This low mutation rate is similar to that
found in human colon cancers, and its significance is unclear (30).
Previous CGH studies found gains of 16p in f40% of BCs (31,
32), with 16p13.3 (containing PDPK1) being the third most (57%)
amplified region in invasive BCs (33). Using whole genome
single-nucleotide polymorphism mapping, we found that
the distribution of tumors with PDPK1 ICN generally clustered
within two separate groups, those with 16p+/16q and those with
many scattered amplicons throughout all of chromosome 16
(Supplementary Fig. S2A). We identified one tumor (case no. 432)
with a relatively narrow amplicon containing f85 genes
(Supplementary Figs. S2A, B and S3). Expression mapping of this
region showed 11 genes (including PDPK1) with at least a 3-fold
increase in expression compared with control (dual channel) and at
least a 10-fold increase in expression compared with the median of
all genes in the sample (single channel; Supplementary Fig. S2B). A
comprehensive genome-wide analysis of both copy number and
message identified six genes (NME3, GFER, E4F1, PDPK1, TCEB2 ,
and HCFC1R1) within this same region that had a strong
correlation between copy number and message (34). Of these six
genes, PDPK1 had the strongest correlation (0.58) and lowest
P value (<0.00012) and only PDPK1 and TCEB2 are found within
the single-nucleotide polymorphism array amplicon peak of case
432 (Supplementary Fig. S2B). Given the more common broad
amplicon in 16p (Supplementary Figs. S2A and S3), PDPK1 is at
least one of possibly several genes whose ICN drives increased
expression.
Although there were a large number of tumors with increased
PDK1 protein levels in the absence of PDPK1 ICN, there was
a significant correlation with PDPK1 ICN and PDK1 mRNA (P =
0.0161; Fig. 1D). Employing protein lysates from fresh frozen
tissue, we found that PDK1 levels are varied in human BC with
a high level of overexpression in the two PDPK1 ICN cases
tested (Supplementary Fig. S1E). In addition, increased PDPK1
copy number was associated with decreased patient survival
[hazard ratio (HR) = 3.14, 95% confidence interval (95% CI) =
1.3–7.6, P = 0.04] independent of age at diagnosis and stage of
disease (Supplementary Fig. S4). This association did not
appreciably change when further adjusted for hormone receptor
status, tumor ploidy, and race (HR = 3.30, 95% CI = 1.3–8.1).
PDPK1 ICN itself was not associated with hormone status
(Supplementary Table S1) or basal cytokeratin expression (data
not shown).
Figure 1. PDK1 is overexpressed with increased
genetic copy number in human BC. A, IHC staining
for PDK1: columnar cell hyperplasia (CCH, 20)
with moderate PDK1 expression (arrow ) adjacent to
normal epithelium (arrowhead ) reflects variable
expression of PDK1 within nonneoplastic duct
epithelium, DCIS (40) with increased PDK1
expression (arrow ), invasive ductal carcinoma
(IDC-1 , 40) with irregular cords of tumor cells
overexpressing PDK1 (arrow ) and adjacent normal
duct (arrowhead). IDC-2 (40) with low level of
PDK1 expression (arrow) and adjacent normal duct
(arrowhead ). B, box plot showing PDK1 IHC score
distribution between BCs versus adjacent normal
ducts, as well as in tumors with PDPK1 ICN
(z5 copies) and tumors without PDPK1 ICN
(V4 copies). C, interphase FISH for PDPK1 (red)
with centromere chromosome 16 control (green )
and indicated number of PDPK1 copies.
D, quantitative reverse transcription-PCR for
PDPK1 mRNA correlated with ICN (by FISH),
comparing ICN cases (relative message quantity
average, 14.0; horizontal line ) compared with cases
without ICN (average, 8.6; horizontal line ) among
BCs with at least 50% tumor density as determined
by H&E staining (n = 57, Spearman coefficient of
rank correlation = 0.321, P = 0.016,
95% CI = 0.066–0.537).
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Increased PDK1 is associated with upstream PI3K pathway
activation. To test the relationship of PDPK1 ICN to known
oncogenes and tumor suppressors that regulate AKT activation,
we compared the pattern of PDPK1 ICN with PIK3CA mutations
(24), PTEN loss (scored by IHC; ref. 24), and ERBB2 amplification
(measured by CISH; ref. 26). At least one of these three lesions
was found in 57% of BCs (Table 1). Importantly, there was an
enrichment of PDPK1 ICN cases among those with at least one
of these upstream activators (82% with an upstream activator
versus 51% without, P = 0.02). This concept that PDPK1 gain
correlated with a second hit on the pathway was validated using
protein lysate arrays on a diverse set of 223 cancer cell lines and
an independent set of 478 BCs (Table 2) in which both total and
phosphorylated S241–specific PDK1 protein levels were mea-
sured. Increased PDK1 protein expression (DPDK1) was found in
BCs with either ERBB2 amplification or PIK3CA mutation
compared with tumors without either of these lesions. In cancer
cell lines, the relationship was again upheld with increased PDK1
levels found coincident with ERBB2 amplification, PIK3CA
mutation, or PTEN mutation, suggesting that this relationship
may be present in other tumor types. Even better correlations
with upstream events were observed for phosphorylated S241
PDK1. A strong association was found between the measure-
ments of total PDK1 and phosphorylated S241–specific PDK1
protein levels in both the tumors (r = 0.57) and cell lines
(r = 0.95) consistent with previous reports of efficient S241
autophosphorylation of PDK1 expressed in bacteria (10) and of
increased phosphorylated S241–specific PDK1 protein levels in
BCs (21, 23).
Increased PDK1 potentiates AKT signaling in the setting of
upstream PI3K pathway activation. Human breast epithelial cell
line MCF10A, immortalized in part through loss of the INK4/ARF
locus (35), has been extensively used to validate BC oncogenes (27).
To determine whether PDK1 overexpression could alter ERBB2-
induced signaling, a set of four MCF10A cell lines were created
from pools of cells infected with retrovirus containing the open
reading frame for PDPK1 (+PDK1), the gene of the activated
mutant rat homologue of ERBB2 (+NeuT; ref. 36), both
Table 1. Association of PDPK1 copy number with upstream PI3K pathway lesions in breast tumors (Columbia cohort)
Pathway lesion Total with lesion (%) No ICN V 4 copies (%) ICN z 5 copies (%) P
ERBB2 amplification (CISH) 19 (16) 14 (14) 5 (22) 0.36*
PTEN loss (IHC) 22 (24) 16 (21) 6 (38) 0.20*
PIK3CA mutation 21 (22) 17 (22) 4 (22) 1.00*
ERBB2 or PTEN 39 (41) 29 (37) 10 (59) 0.10
ERRB2 or PIK3CA 35 (36) 26 (33) 9 (50) 0.16
PTEN or PIK3CA 42 (45) 32 (42) 10 (63) 0.13
ERBB2 or PTEN or PIK3CA 54 (57) 40 (51) 14 (82) 0.02
c
*P value was from Fisher’s exact test; all other P values were from m2 test.
cP < 0.05 denoting significant enrichment in the number of breast cancers with PDPK1 ICN (z5 copies) among those with upstream PI3K pathway
activating lesions (as noted) and the remainder of cases.
Table 2. Association of PDK1 protein expression with upstream PI3K pathway lesions
Pathway lesion Total with lesion (%) DPDK1* total (P) DPDK1* p-S241 (P)
Cancer cell lines
ERBB2 amplification 6 (3) 0.00 (0.973) 0.10 (0.222)
PTEN mutation 54 (24) 0.08 (0.069) 0.06 (0.221)
PIK3CA mutation 27 (12) 0.10 (0.260) 0.21 (0.061)
ERBB2 or PTEN 60 (27) 0.07 (0.077) 0.07 (0.147)
ERRB2 or PIK3CA 33 (15) 0.09 (0.252) 0.20 (0.034)
c








Breast tumors (MD Anderson cohort)
ERBB2 amplification 20 (12) 0.216 (0.106) 0.375 (0.026)
c
PIK3CA mutation 89 (24) 0.021 (0.859) 0.305 (0.002)
c




*Reverse-phase protein lysate arrays probed with total PDK1 or p-S241 PDK1 antibodies. DPDK1 = magnitude difference in the mean signal from each
antibody in the set of cases defined by a particular PI3K pathway alteration (denoted by the column heading ‘‘pathway lesion’’) minus the mean signal
from the remainder of cases.
cP < 0.05 (two-tailed t test).
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(+PDK1+NeuT), or empty vector controls. Consistent with the
function of PDK1 as a selective T-308 AKT kinase, overexpression
of PDK1 alone increased AKT phosphorylation on residue T-308
but had no effect on serine-473 (S-473), whereas NeuT over-
expression alone increased both (Fig. 2A). When PDK1 and NeuT
were both overexpressed, there were significant increases in both
phosphorylation of T-308 and, surprisingly, S-473 over that of either
PDK1 or NeuT overexpression alone, with a more pronounced
relative activation in the setting of serum starvation. Consistent
with this narrower and less pronounced effect on AKT signaling,
increasing PDK1 levels alone was not sufficient to induce serum-
starved MCF10A proliferation but did enhance growth when added
to NeuT (Supplementary Fig. S5A).
To determine whether increased PDK1 levels enhanced PI3K
signaling induced by other genetic aberrations found in BCs,
we knocked down PTEN expression in MCF10A cells and over-
expressed PDK1 in PIK3CA mutantMCF7 cells. Aswith +PDK1+NeuT,
increasing PDK1 levels in the context of reduced PTEN or mu-
tant PIK3CA enhanced activation of AKT as indicated by in-
creased phosphorylation of T-308 and S-473 (Supplementary Fig. S5B
and C).
Increased PDK1 potentiates ERBB2-induced transformation
and migration. To assess the biological affect of the enhancement
of signaling of PDK1, we chose to assess elevated PDK1 levels in
combination with ERBB2 because unlike PTEN or PI3K, ERBB2
activates multiple signaling pathways, such as the RAS/mitogen-
activated protein kinase pathway, which can lead to evidence of
oncogene cooperation. ERBB2 alone partially transforms MCF10A
cells in three-dimensional culture, forming large multiacinar
structures (37). In a three-dimensional culture, addition of PDK1
did not alter the control MCF10A phenotype (Fig. 2B). However,
overexpression of PDK1 had a profound effect on the morphology
of +NeuT cells in which multiacinar structures were distorted and
cell foci were linked by interconnecting branching tracts. IHC
analysis revealed a more complete epithelial-to-mesenchymal
transition and decreased central acinar apoptosis within the
+PDK1+NeuT structures compared with those of +NeuT (Supple-
mentary Fig. S6A).
Given the extensive branching seen in the +PDK1+NeuT three-
dimensional foci, we tested the capacity of the cells to migrate.
Consistent with published data showing that PDK1 kinase activity
is required for PI3K-dependent cell migration (38), we found that
PDK1 overexpression alone increased migration toward a chemo-
attractant, but had no effect when the chemoattractant was
withheld (Fig. 2C). Overexpression of NeuT alone allowed cells to
migrate without a chemoattractant signal, yet they migrated 3-fold
more toward the chemoattractant. +PDK1+NeuT cells showed
increased migration to the same extent as +NeuT regardless of the
presence of a chemoattractant, suggesting that the cells had
completely uncoupled their migratory machinery from extracellu-
lar growth factor sensing. This effect was confirmed with a scratch
test performed under serum-starved conditions (Supplementary
Fig. S6B). Strikingly, knockdown of AKT2 inhibited PDK1-induced
migration, whereas knockdown of AKT1 promoted migration
(Fig. 2D), consistent with previous reports implicating AKT2 in
motility and metastasis (39).
Increased PDK1 potentiates tumor growth in vivo . To test
whether these effects could confer tumor growth in vivo , +NeuT
cells or +PDK1+NeuT cells were injected into the inferior
mammary fat pads of developing scid mice (n = 10 in each
cohort). +PDK1+NeuT cells rapidly produced large muscle invasive
tumors in all mice requiring sacrifice at a median of 30 days,
whereas +Ne2uT cells formed only one tumor (sacrificed on day
50) after 140 days of observation (P < 0.0001; Fig. 3A and B).
Control MCF10A cells and those overexpressing PDK1 alone did
not form tumors (n = 5 in each cohort). The same combination of
PDK1 and ERBB2 expressed in HMEC-hTERT cells failed to form
tumors (n = 10).
Figure 2. Overexpression of PDK1 enhances oncogenic phenotype in setting of
upstream PI3K activation. A, immunoblots showing signaling effects of
overexpressed PDK1 and NeuT on MCF10A cells under normal exponential
growth or growth factor withdrawal conditions. B, Matrigel morphogenesis assay
of stably transfected pools of MCF10A cells as indicated. C, transwell migration
assay with same set of cells with and without chemoattractant (epidermal
growth factor and 5% horse serum; SD, n = 3). D, migration assay of control
MCF10A cells or those with PDK1 overexpression with small interfering RNA
knockdown of AKT1, AKT2, or both. Migration (y axis) = ratio of the number of
migratory cells in test versus control (SD, n = 3).
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In cells with PI3K activation, PDK1 levels are a determinant
of signaling, proliferation, transformation, and pathway
inhibition. Given potential off-target effects from either RNAi or
drug inhibition of PDK1 (40–42), both methods were used to show
the effects of altered PDK1 levels on cell proliferation and signaling.
Stable RNAi knockdown of PDK1 in cells harboring PIK3CA
mutation decreased both AKT and downstream GSK3 activation in
MCF7 cells (Fig. 4A) with corresponding decreased proliferation of
MCF7 (Fig. 4B) and T47D (Supplementary Fig. S7A) cells, all in a
dose-dependent manner. The relatively selective PDK1 inhibitor
BX-795 (ref. 43; also shown to inhibit Aurora A, Aurora B, Aurora C,
Cdk1, and Cdk2; refs. 40, 42) inhibited growth factor–stimulated
AKT T-308 phosphorylation in MCF10A cells with 50% signal
inhibition corresponding to its measured IC50 of 1 Amol/L
(Supplementary Fig. S7B). Increasing PDK1 levels in MCF7 cells
made them more resistant to BX-795 (Fig. 4C) and decreasing
PDK1 levels made them more sensitive (67% inhibition in control
cells compared with 83% in the potent knockdown line; Fig. 4B),
arguing that the level of PDK1 is a significant determinant of
BX-795 activity.
We also found that transformation of cells via a PIK3CA kinase
domain mutation (H1047R) was dependent on PDK1. Decreasing
PDK1 levels inhibited colony formation in soft agar and growth of
immortalized human mammary epithelial cells (HMEC/hTERT/
p53DD) stably expressing mutant p110a (H1047R; Fig. 4D ;
Supplementary Fig. S7C). In the same cell background (HMEC/
hTERT/p53DD/H1047R), overexpression of PDK1 conferred resis-
tance to the selective PI3K inhibitor wortmannin (Supplementary
Fig. S7D–F). Consistent with PDK1K465E/K465E knock-in mouse data
showing that PDK1 membrane localization is necessary for optimal
AKT activation (9), cells expressing myristolated PDK1 were more
resistance than wild-type PDK1 expressing cells to PI3K inhibition
(Supplementary Fig. S7D). This suggests that the amount of PDK1
at the membrane is a determinant of resistance to pathway
inhibition and highlights another potential mechanism to thera-
peutically target PDK1 other than through its kinase domain.
Discussion
We have shown that total PDK1 protein and message up-
regulation is present in almost three quarters of BCs tested, making
it a common lesion of the PI3K pathway in BC. We have found that
total PDK1 levels correlate strongly with S241 phosphorylated PDK1
levels, which suggests that it also is, at least in part, a measure of
total PDK1 expression. We have found that one mechanism for
PDK1 up-regulation occurs through an increase in gene copy
number within 16p13.3 amplicons (Fig. 1), the third most frequently
amplified region in BCs (33). However, PDPK1 ICN can only explain
a portion of cases with PDK1 overexpression, which suggests that
additional mechanisms of overexpression remain to be elucidated.
Our data strongly argues that PDK1 overexpression coordinately
occurs with upstream PI3K activation to contribute to BC
progression, because we see that both PDK1 ICN and protein
expression are associated in tumors to upstream PI3K pathway
lesions of PIK3CA, ERBB2 , or PTEN (Tables 1 and 2). The link
between PDK1 and PI3K signaling is further substantiated by the
observation that PDPK1 ICN is associated with poor prognosis
(Supplementary Fig. S4), which has also been established for
activation of the PI3K pathway (44) and by findings by others that
16p13.3 gains correlate with gains of 17q12, the ERBB2 locus (33).
In addition to BC, we identified a coordinated increase of PDK1
with upstream PI3K pathway lesions in tumor cell lines represent-
ing a large variety of cancer. These findings suggest that PDK1
overexpression may cooperate with upstream PI3K pathway lesions
in a wide variety of solid tumors to promote tumor progression by
further activating the PI3K pathway.
Our data from human BCs, tissue culture, and xenografted
tumors provide evidence for a model of tumor development in
which BCs are selected to increase PDK1 to potentiate upstream
lesions of the PI3K pathway for increased signaling and as a
consequence tumor progression. Given that both PDPK1 ICN and
increased PDK1 protein levels in human BCs correlate with either
one of three activators of PI3K signaling (ERBB2 amplification,
PIK3CA mutation, or PTEN down-regulation), we hypothesized
that the effect of PDK1 up-regulation is likely to be an increased
signal output. Our data from experiments with cultured mammary
cells support this conclusion, because PDK1 overexpression, in the
setting of upstream activation by ERBB2 or mutant PIK3CA or
PTEN loss, increased phosphorylation of its substrate AKT T-308 as
Figure 3. Increased PDK1 potentiates tumor growth in vivo. A, Kaplan-Meier
survival curves of MCF10A cells injected into the mammary fatpads of
developing scid mice, comparing cells overexpressing NeuT with
(+PDK1+NeuT, narrow dashed line ) or without (+NeuT, solid line ) overex-
pressed PDK1 (death is defined as tumor growth to size = 1 cm2). Injected
control MCF10A cells and
cells overexpressing PDK1 alone did not form tumors (wide dashed line). B, IHC
staining (left, H&E; right, HA antibody to HA-tagged PDK1, 40) of xenografted
tumor cells (arrows ) invading host muscle (arrowheads ).
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well as AKT S-473 (Fig. 2). The model asserts that, in cells with
increased levels of PIP3, coordinate gain of PDK1 potentiates the
PI3K pathway signal to a level that maintains downstream pathway
activation. The most likely mechanism of such intrapathway
enhancement involving overexpression of PDK1 is the direct
boosting of the signal from a defined static amount of PIP3 due to
an upstream lesion in PIK3CA, ERBB2 , or PTEN .
PDK1 levels had their most prominent potentiating effect on the
PI3K signal due to an upstream pathway lesion when growth factor
input was low (serum starvation). Therefore, PDK1 is limiting
under these conditions, perhaps recreating the selective pressure
for increasing PDK1 levels found in tissues during the stress
associated with tumor development. In support of this idea, a 90%
reduction of PDK1 protein expression did not significantly affect
ligand-activated insulin signaling in normal mice (45), whereas the
same PDK1 hypomorph significantly attenuated tumor formation
in Pten heterozygous mice (22).
We have documented that the potentiating effect of PDK1 on the
PI3K signal is sufficient to have phenotypic effects on mammary
cells (Fig. 2). PDK1 increased proliferation, migration, and
epithelial-to-mesenchymal transition and reduced apoptosis in
ERBB2 MCF10A cells. The combination of ERBB2 and PDK1 in this
immortal cell line was even sufficient to cause tumor formation in
the mammary fat pad of scid mice in all mice tested when either
gene alone had little or no effect (Fig. 3). It will be interesting to
determine whether PDK1 overexpression in combination with
PIK3CA mutation or reduced PTEN expression in MCF10A cells
phenocopies PDK1/ERBB2; however, we anticipate that they will be
less oncogenic given their weaker ability to activate other signaling
pathways.
We suspect that many of the consequences of PDK1 over-
expression occur via the activation of different AKT isoforms and
have shown that increased migration flows through AKT2 (Fig. 2).
These data are consistent with a transgenic mouse model of
concurrent ERBB2 and AKT1 overexpression showing acceleration
of mammary tumor progression but lower levels of invasion (46)
and argues that PDK1 overexpression may be a more efficient and
potent PI3K pathway potentiator than any one of its substrates.
PDK1 phosphorylates other AGC kinase substrates, including
p70S6 kinase and SGK1 in a PI3K pathway–dependent manner
(47), and these outputs are likely to be enhanced by PDK1
overexpression as well. In addition, PDK1 regulation of other AGC
kinases remains an active area of investigation that may expose the
functional role of additional PI3K-regulated substrates.
Evidence for different PI3K pathway lesions co-occurring in the
same tumor has been shown in endometrial cancers, wherein PTEN
disruption through gene mutation and loss of protein expression are
frequently coincident with PIK3CA mutation or amplification and
together provide increased PI3K signal output (48). It is possible that
in endometrial cancers, the level of PIP3 may be limiting and thus
the determinants of the PI3K signal could be tissue specific,
although it is not known whether PDK1 makes a contribution in
these tumors. Alternatively, if PDK1 levels are found to be
coincidentally increased in this setting, it would argue that tumors
using an active PI3K pathway undergo continual selection for
increased PDK1 to maintain a high signal output. Because we
observe increased PDK1 levels in the ductal carcinoma in situ (DCIS)
component of invasive tumors expressing high levels of PDK1, one
could imagine a scenario in which ERBB2 amplification is followed
by PDK1 overexpression and subsequent PIK3CA mutation, as well
as possibly other events, all to ratchet up the level of PI3K signaling.
The ability of endogenous PDK1 to contribute to PI3K
signaling and tumor cell proliferation was also documented in
tumor cells harboring PIK3CA mutations, which suggests that
PDK1 amplification of PI3K signaling outputs stimulates tumor
growth (Fig. 4). Our data also show that increasing PDK1 levels, at
Figure 4. In cells with PI3K activation, PDK1 levels
are a determinant of signaling, proliferation,
transformation, and pathway inhibition. A, immunoblots
of MCF7 cells grown with stable control shRNA
(CTRL ) or two separate PDK1 shRNA contructs
(PDK1-1 and PDK1-2 ). B, MCF7 cells with stable
control shRNA or separate PDK1 shRNA contructs
(as indicated) grown for 4 d with 1.25 Amol/L BX-795
(orange columns ) or control (DMSO, blue columns ;
percentage of inhibition is indicated, SD, n = 3).
C, BX-795 dose-response curves of control MCF7 cells
or MCF7 cells overexpressing PDK1 with the IC50
indicated (dotted lines ; SD, n = 3). D, colony formation
assay of HMEC/hTERT/p53DD cells overexpressing
mutant p110a (H1047R ) or control, or p110a
(H1047R ) in the setting of stable PDK1 shRNA
compared with control shRNA.
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least in some settings, could contribute to resistance to inhibitors
of the PI3K pathway at the level of PDK1 and PI3K (Fig. 4).
Thus, we conclude that PDK1 overexpression in tumors
increases the level of oncogenic PI3K signal due to pathogenetic
activation of PI3K or inactivation of PTEN. Our findings suggest
that PDK1 levels should be taken into account in any attempt to
assess derangements of the PI3K pathway in cancer and that
targeting PDK1 along with other components of the PI3K pathway
simultaneously may be a useful approach in cancer therapy.
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